{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:17:36Z","timestamp":1790806656723,"version":"4.1.0"},"reference-count":224,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Ironically, population aging which is considered a public health success has been accompanied by a myriad of new health challenges, which include neurodegenerative disorders (NDDs), the incidence of which increases proportionally to age. Among them, Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD) are the most common, with the misfolding and the aggregation of proteins being common and causal in the pathogenesis of both diseases. AD is characterized by the presence of hyperphosphorylated \u03c4 protein (tau), which is the main component of neurofibrillary tangles (NFTs), and senile plaques the main component of which is \u03b2-amyloid peptide aggregates (A\u03b2). The neuropathological hallmark of PD is \u03b1-synuclein aggregates (\u03b1-syn), which are present as insoluble fibrils, the primary structural component of Lewy body (LB) and neurites (LN). An increasing number of non-invasive PET examinations have been used for AD, to monitor the pathological progress (hallmarks) of disease. Notwithstanding, still the need for the development of novel detection tools for other proteinopathies still remains. This review, although not exhaustively, looks at the timeline of the development of existing tracers used in the imaging of A\u03b2 and important moments that led to the development of these tracers.<\/jats:p>","DOI":"10.3390\/molecules25040977","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T03:21:16Z","timestamp":1582773676000},"page":"977","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["PET Radiopharmaceuticals for Alzheimer\u2019s Disease and Parkinson\u2019s Disease Diagnosis, the Current and Future Landscape"],"prefix":"10.3390","volume":"25","author":[{"given":"Bright Chukwunwike","family":"Uzuegbunam","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, and Neuroimaging Center, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Librizzi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Philipps-University of Marburg, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-4449","authenticated-orcid":false,"given":"Behrooz","family":"Hooshyar Yousefi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, and Neuroimaging Center, Technical University of Munich, 81675 Munich, Germany"},{"name":"Department of Nuclear Medicine, Philipps-University of Marburg, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"ref_1","unstructured":"Alzheimer\u2019s Disease International (2015). The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends, Alzheimer\u2019s Disease International. World Alzheimer Report 2015."},{"key":"ref_2","unstructured":"Alzheimer\u2019s Disease International (2018). World Alzheimer Report 2018\u2014The State of the Art of Dementia Research: New Frontiers, Alzheimer\u2019s Disease International."},{"key":"ref_3","unstructured":"World Health Organisation-Alzheimer\u2019s Disease International (2012). Dementia: A Public Health Priority, WHO."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Trevisan, K., Cristina-Pereira, R., Silva-Amaral, D., and Aversi-Ferreira, T.A. (2019). Theories of Aging and the Prevalence of Alzheimer\u2019s Disease. Biomed. Res. Int., 1\u20139.","DOI":"10.1155\/2019\/9171424"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"648740","DOI":"10.1155\/2014\/648740","article-title":"Shared mechanisms of neurodegeneration in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"2014","author":"Xie","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer\u2019s disease and the amyloid-beta peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"(2018). Alzheimer\u2019s Association 2018 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 14, 367\u2013429.","DOI":"10.1016\/j.jalz.2018.02.001"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-6606-4-3","article-title":"APP processing in Alzheimer\u2019s disease","volume":"4","author":"Zhang","year":"2011","journal-title":"Mol. Brain"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/jnc.12202","article-title":"Alzheimer\u2019s A\u03b242 and A\u03b240 peptides form interlaced amyloid fibrils","volume":"126","author":"Gu","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.3233\/JAD-2012-129001","article-title":"Molecular mechanisms of amyloid oligomers toxicity","volume":"33","author":"Kayed","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0197-4580(97)00075-4","article-title":"Strategies for Improving the Postmortem Neuropathological Diagnosis of Alzheimer\u2019s Disease","volume":"18","author":"Trojanowski","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref_13","first-page":"133","article-title":"Les diagnostics de la maladie d\u2019Alzheimer","volume":"56","author":"Delacourte","year":"1998","journal-title":"Ann. Biol. Clin. (Paris)"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3233\/JAD-141134","article-title":"Epidemiological and economic burden of Alzheimer\u2019s disease: A systematic literature review of data across Europe and the United States of America","volume":"43","author":"Takizawa","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"a006213","DOI":"10.1101\/cshperspect.a006213","article-title":"Brain imaging in Alzheimer disease","volume":"2","author":"Johnson","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/NRL.0b013e31826a998d","article-title":"New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician","volume":"18","author":"Budson","year":"2012","journal-title":"Neurologist"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_19","first-page":"108","article-title":"The Role of Genetics in Advancing Precision Medicine for Alzheimer\u2019s Disease-A Narrative Review","volume":"5","author":"Li","year":"2018","journal-title":"Front. Med. (Lausanne)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/NRL.0b013e318187e76b","article-title":"Genetic aspects of Alzheimer disease","volume":"15","author":"Williamson","year":"2009","journal-title":"Neurologist"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.euroneuro.2011.08.003","article-title":"Qualification opinion of novel methodologies in the predementia stage of Alzheimer\u2019s disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden\u2014Regulatory considerations by European Medicines Agency focusing in improving benefit\/risk in regulatory trials","volume":"21","author":"Isaac","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/npp.2013.154","article-title":"Biomarkers in amyloid-\u03b2 immunotherapy trials in Alzheimer\u2019s disease","volume":"39","author":"Blennow","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jalz.2007.08.006","article-title":"Core candidate neurochemical and imaging biomarkers of Alzheimer\u2019s disease","volume":"4","author":"Hampel","year":"2008","journal-title":"Alzheimers Dement."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000311703","article-title":"Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients","volume":"63","author":"Zetterberg","year":"2010","journal-title":"Eur. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.neuroimage.2011.11.075","article-title":"Brain imaging in the study of Alzheimer\u2019s disease","volume":"61","author":"Reiman","year":"2012","journal-title":"Neuroimage"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1021\/cn500103u","article-title":"High Affinity Radiopharmaceuticals Based Upon Lansoprazole for PET Imaging of Aggregated Tau in Alzheimer\u2019s Disease and Progressive Supranuclear Palsy: Synthesis, Preclinical Evaluation, and Lead Selection","volume":"5","author":"Fawaz","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1126\/science.1090349","article-title":"Looking backward to move forward: early detection of neurodegenerative disorders","volume":"302","author":"DeKosky","year":"2003","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bailey, D.L., Maisey, M.N., Townsend, D.W., and Valk, P.E. (2005). Positron Emission Tomography. Basic Sciences, Springer-Verlag London Limited.","DOI":"10.1007\/b136169"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1039\/C6CS00492J","article-title":"Fluorine-18 labelled building blocks for PET tracer synthesis","volume":"46","author":"Pees","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"ref_31","first-page":"268","article-title":"18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer\u2019s disease","volume":"8","author":"Filippi","year":"2018","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2174\/1381612043384772","article-title":"Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain","volume":"10","author":"Mathis","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/bc500475e","article-title":"Fluorine-18 radiochemistry, labeling strategies and synthetic routes","volume":"26","author":"Jacobson","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1021\/jm5017544","article-title":"Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future","volume":"58","author":"Ariza","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3233\/JAD-2011-0068","article-title":"Florbetaben to trace amyloid-\u03b2 in the Alzheimer brain by means of PET","volume":"26","author":"Barthel","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","article-title":"Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","article-title":"18FFlutemetamol amyloid-beta PET imaging compared with 11CPIB across the spectrum of Alzheimer\u2019s disease","volume":"41","author":"Hatashita","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.arcmed.2010.03.007","article-title":"The revitalized tau hypothesis on Alzheimer\u2019s disease","volume":"41","author":"Maccioni","year":"2010","journal-title":"Arch. Med. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/fnl.12.34","article-title":"The challenges of tau imaging","volume":"7","author":"Villemagne","year":"2012","journal-title":"Future Neurol."},{"key":"ref_43","first-page":"873270","article-title":"Lessons from tau-deficient mice","volume":"2012","author":"Ke","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-1331.2008.02513.x","article-title":"Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options","volume":"16","author":"Ludolph","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","article-title":"The role of tau in Alzheimer\u2019s disease and related disorders","volume":"17","author":"Medeiros","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_46","unstructured":"(2019, December 22). Winners. Available online: https:\/\/www.eanm.org\/congresses-events\/awards-grants\/winners\/."},{"key":"ref_47","unstructured":"Vanhaute, H., Ceccarini, J., Michiels, L., Koole, M., Emsell, L., Lemmens, R., Vandenbulcke, M., and van Laere, K. (2019). PET-MR Imaging of Tau and Synaptic Density in Prodromal Alzheimer\u2019s Disease, Alzheimer\u2019s Disease International."},{"key":"ref_48","unstructured":"(2019, November 20). U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/j.jalz.2014.04.013","article-title":"In vivo tau imaging: obstacles and progress","volume":"10","author":"Villemagne","year":"2014","journal-title":"Alzheimers Dement."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","article-title":"The development and validation of tau PET tracers: current status and future directions","volume":"6","author":"Okamura","year":"2018","journal-title":"Clin. Transl. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","article-title":"Autoradiography validation of novel tau PET tracer F-18-MK-6240 on human postmortem brain tissue","volume":"7","author":"Aguero","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","article-title":"Discovery and preclinical characterization of 18FPI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies","volume":"46","author":"Kroth","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1749-6632.2000.tb06900.x","article-title":"The alpha-synucleinopathies: Parkinson\u2019s disease, dementia with Lewy bodies, and multiple system atrophy","volume":"920","author":"Spillantini","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0304-3940(98)00407-8","article-title":"\u03b1-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy","volume":"249","author":"Wakabayashi","year":"1998","journal-title":"Neuroscience Letters"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ana.410440324","article-title":"Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein","volume":"44","author":"Tu","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Sharma","year":"2010","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.1073\/pnas.0712179105","article-title":"The fold of alpha-synuclein fibrils","volume":"105","author":"Vilar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"Fukushima","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E","article-title":"Synucleins in synaptic plasticity and neurodegenerative disorders","volume":"58","author":"Clayton","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"\u03b1-synuclein locus duplication as a cause of familial Parkinson\u2019s disease","volume":"364","author":"Kachergus","year":"2004","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","article-title":"Causal relation between \u03b1-synuclein locus duplication as a cause of familial Parkinson\u2019s disease","volume":"364","author":"Bonnet","year":"2004","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00441-018-2817-y","article-title":"Genetic risk factors in Parkinson\u2019s disease","volume":"373","author":"Billingsley","year":"2018","journal-title":"Cell Tissue Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/ng.3955","article-title":"A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci","volume":"49","author":"Chang","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Nalls, M., Blauwendraat, C., Vallerga, C.L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D.A., Noyce, A.J., and Xue, A. Parkinson\u2019s disease genetics: Novel risk loci, genomic context, causal insights and heritable risk. BiorRxiv, 2018.","DOI":"10.1101\/388165"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.brainresrev.2010.05.006","article-title":"Neuroimaging for Lewy body disease: is the in vivo molecular imaging of \u03b1-synuclein neuropathology required and feasible?","volume":"65","author":"Vernon","year":"2010","journal-title":"Brain Res. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/mds.22242","article-title":"The prodromal phase of sporadic Parkinson\u2019s disease: does it exist and if so how long is it?","volume":"23","author":"Hawkes","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.20226","article-title":"Parkinsonian signs and substantia nigra neuron density in decendents elders without PD","volume":"56","author":"Ross","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF01249445","article-title":"Time course of nigrostriatal degeneration in parkinson\u2019s disease. A detailed study of influential factors in human brain amine analysis","volume":"38","author":"Riederer","year":"1976","journal-title":"J. Neural Transm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.jnen.0000205145.54457.ea","article-title":"Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies","volume":"65","author":"Deramecourt","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2967\/jnumed.113.136515","article-title":"Molecular imaging insights into neurodegeneration: focus on \u03b1-synuclein radiotracers","volume":"55","author":"Shah","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.brainres.2015.06.002","article-title":"Post-translational modification of \u03b1-synuclein in Parkinson\u2019s disease","volume":"1628","author":"Barrett","year":"2015","journal-title":"Brain Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of \u03b1-synuclein and A\u03b2 in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.semnuclmed.2017.06.003","article-title":"Small-molecule PET Tracers for Imaging Proteinopathies","volume":"47","author":"Mathis","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s40336-016-0217-4","article-title":"Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites","volume":"5","author":"Kotzbauer","year":"2017","journal-title":"Clin. Transl. Imaging"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.2174\/0929867323666160418114826","article-title":"Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging","volume":"23","author":"Pike","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.mibio.2003.09.009","article-title":"Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography","volume":"5","author":"Laruelle","year":"2003","journal-title":"Mol. Imaging Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41181-016-0016-2","article-title":"Strategies to facilitate the discovery of novel CNS PET ligands","volume":"1","author":"Zhang","year":"2017","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1021\/ar500233s","article-title":"A philosophy for CNS radiotracer design","volume":"47","author":"Ricq","year":"2014","journal-title":"Acc. Chem. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/10520298809107185","article-title":"Methods for staining amyloid in tissues: A review","volume":"63","author":"Elghetany","year":"1988","journal-title":"Stain Technol."},{"key":"ref_88","first-page":"487","article-title":"Fluorescent stains, with special reference to amyloid and connective tissues","volume":"68","author":"Vassar","year":"1959","journal-title":"Arch. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1021\/acschemneuro.6b00450","article-title":"Novel Benzothiazole Derivatives as Fluorescent Probes for Detection of \u03b2-Amyloid and \u03b1-Synuclein Aggregates","volume":"8","author":"Watanabe","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2174\/1568026611313080004","article-title":"Fluorine-18 radiolabeled heterocycles as PET tracers for imaging \u03b2-amyloid plaques in Alzheimer\u2019s disease","volume":"13","author":"Zeng","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","article-title":"Development of positron emission tomography \u03b2-amyloid plaque imaging agents","volume":"42","author":"Mathis","year":"2012","journal-title":"Semin. Nucl. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0024-3205(01)01232-2","article-title":"Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain","volume":"69","author":"Klunk","year":"2001","journal-title":"Life Sciences"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003","article-title":"The Binding of 2-(4\u2032-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component","volume":"23","author":"Klunk","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","article-title":"Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents","volume":"46","author":"Mathis","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","article-title":"Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B","volume":"25","author":"Price","year":"2005","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0960-894X(01)00734-X","article-title":"A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain","volume":"12","author":"Mathis","year":"2002","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e318188c0c8","article-title":"Whatever happened to Pittsburgh Compound-A?","volume":"22","author":"Klunk","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","article-title":"11CPIB in a nondemented population: potential antecedent marker of Alzheimer disease","volume":"67","author":"Mintun","year":"2006","journal-title":"Neurology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chroma.2007.10.084","article-title":"Efficient purification and metabolite analysis of radiotracers using high-performance liquid chromatography and on-line solid-phase extraction","volume":"1189","author":"Chitneni","year":"2008","journal-title":"J. Chromatogr. A"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1021\/jm8013376","article-title":"Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer\u2019s disease","volume":"52","author":"Serdons","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/S0197-4580(04)80924-2","article-title":"P2-178 Species-dependent formation and identification of the brain metabolites of the amyloid imaging agent [11C]PIB","volume":"25","author":"Mathis","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1471-4159.2010.06812.x","article-title":"Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand","volume":"114","author":"Swahn","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jlcr.2989","article-title":"Positron emission tomography radioligands for in vivo imaging of A\u03b2 plaques","volume":"56","author":"Mason","year":"2013","journal-title":"J. Labelled Comp. Radiopharm."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-012-2178-9","article-title":"Pharmacokinetics of \u00b9\u2078Fflutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer\u2019s disease","volume":"39","author":"Snellman","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamaneurol.2014.4143","article-title":"The translational journey of brain \u03b2-amyloid imaging: from positron emission tomography to autopsy to clinic","volume":"72","author":"Rabinovici","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_108","unstructured":"GE Healthcare (2016, September 15). Gehealthcare Vizamyl Prescribing Information. Available online: http:\/\/www3.gehealthcare.com\/~\/media\/documents\/us-global\/products\/nuclear-imaging-agents_non-gatekeeper\/clinical%20product%20info\/vizamyl\/gehealthcare-vizamyl-prescribing-information.pdf."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainres.2004.08.004","article-title":"Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer\u2019s disease","volume":"1025","author":"Kung","year":"2004","journal-title":"Brain Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0969-8051(03)00049-0","article-title":"11C-labeled stilbene derivatives as A\u03b2-aggregate-specific PET imaging agents for Alzheimer\u2019s disease","volume":"30","author":"Ono","year":"2003","journal-title":"Nucl. Med. Biol."},{"key":"ref_111","first-page":"584","article-title":"In-vivo imaging of Alzheimer disease beta-amyloid with 11CSB-13 PET","volume":"12","author":"Verhoeff","year":"2004","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1021\/jm050166g","article-title":"F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain","volume":"48","author":"Zhang","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/bc060239q","article-title":"Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates","volume":"18","author":"Stephenson","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.nucmedbio.2005.06.001","article-title":"F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain","volume":"32","author":"Zhang","year":"2005","journal-title":"Nucl. Med. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/jm901039z","article-title":"18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer\u2019s disease: A miniperspective","volume":"53","author":"Kung","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid \u03b2 in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_117","unstructured":"(2020, February 20). Frequently Asked Questions about Beta-Amyloid Imaging, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204677s000lbl.pdf."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nucmedbio.2006.10.003","article-title":"18F-labeled styrylpyridines as PET agents for amyloid plaque imaging","volume":"34","author":"Zhang","year":"2007","journal-title":"Nucl. Med. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","article-title":"Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain","volume":"50","author":"Choi","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir corrected F 18)","volume":"51","author":"Wong","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_121","first-page":"890","article-title":"Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer\u2019s disease","volume":"13","author":"Okamura","year":"2010","journal-title":"IDrugs"},{"key":"ref_122","unstructured":"Kolata, G. (2019, December 05). Promise Seen for Detection of Alzheimer\u2019s. Available online: https:\/\/www.nytimes.com\/2010\/06\/24\/health\/research\/24scans.html."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1471-4159.2008.05861.x","article-title":"AZD2184: A radioligand for sensitive detection of beta-amyloid deposits","volume":"108","author":"Johnson","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1016\/j.bmcl.2012.05.011","article-title":"Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as \u00b9\u2078F-PET imaging agents for \u03b2-amyloid plaques","volume":"22","author":"Swahn","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","article-title":"Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease","volume":"50","author":"Nelissen","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_126","unstructured":"Mathis, C., Lopresti, B., Mason, N., Price, J., Flatt, N., Bi, W., Ziolko, S., DeKosky, S., and Klunk, W. (2019, December 06). Comparison of the Amyloid Imaging Agents [F-18]3\u2032-F-PIB and [C-11]PIB in Alzheimer\u2019s Disease and Control Subjects. Available online: http:\/\/jnm.snmjournals.org\/content\/48\/supplement_2\/56P.3.short."},{"key":"ref_127","first-page":"1959","article-title":"Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis","volume":"46","author":"Lopresti","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.111.094029","article-title":"Clinical validation of 18F-AZD4694, an amyloid-\u03b2-specific PET radioligand","volume":"53","author":"Forsberg","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_129","unstructured":"(2019, December 06). A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology-Full Text View-ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01886820."},{"key":"ref_130","unstructured":"(2019, December 06). Flutafuranol F 18-Navidea Biopharmaceuticals-AdisInsight. Available online: https:\/\/adisinsight.springer.com\/drugs\/800031066."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.nucmedbio.2011.04.004","article-title":"18FFluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey","volume":"38","author":"Hostetler","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"ref_132","unstructured":"(2019, December 06). Merck Clinical Trials. Available online: https:\/\/www.merck.com\/clinical-trials\/study.html?id=3328-002&kw=alzheimer%27s&tab=eligibility."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/ml200123w","article-title":"A Novel (18)F-Labeled Imidazo2,1-bbenzothiazole (IBT) for High-Contrast PET Imaging of \u03b2-Amyloid Plaques","volume":"2","author":"Yousefi","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1186\/s13550-015-0090-6","article-title":"FIBT versus florbetaben and PiB: A preclinical comparison study with amyloid-PET in transgenic mice","volume":"5","author":"Yousefi","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_135","unstructured":"Westwell, A.D. (2015). Fluorinated Pharmaceuticals. Development of 18F-labeled compounds for imaging of A\u03b2 plaques by means of PET., Future Science Ltd."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/cn5001827","article-title":"Characterization and first human investigation of FIBT, a novel fluorinated A\u03b2 plaque neuroimaging PET radioligand","volume":"6","author":"Yousefi","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000492151","article-title":"A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice","volume":"46","author":"Kim","year":"2018","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","article-title":"Clinical Use and Utility of Amyloid Imaging","volume":"58","author":"Barthel","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","article-title":"Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"52","author":"Chiotis","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_140","unstructured":"Ceccaldi, M., Jonveaux, T., Verger, A., Salmon, P.K., Houzard, C., Godefroy, O., Shields, T., Perrotin, A., Gismondi, R., and Bullich, S. (2020, February 08). Impact of Florbetaben PET Imaging on Diagnosis and Management of Patients with Suspected Alzheimer\u2019s Disease Eligible for CSF Analysis in France. Available online: http:\/\/jnm.snmjournals.org\/content\/58\/supplement_1\/561?related-urls=yes&legid=jnumed;58\/supplement_1\/561."},{"key":"ref_141","unstructured":"Hattori, N., Ono, S., UDO, N., Yamamoto, S., Ogawa, M., and Sugie, H. (2020, February 08). Clinical Impact of F-18 Flutemetamol (FMM) PET to Assess Cerebral A\u00df Pathology in Patients with Various Cognitive Disorders. Available online: http:\/\/jnm.snmjournals.org\/content\/59\/supplement_1\/480."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00259-019-04297-5","article-title":"Clinical impact of 18Fflutemetamol PET among memory clinic patients with an unclear diagnosis","volume":"46","author":"Leuzy","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","article-title":"Beta-amyloid imaging with florbetaben","volume":"3","author":"Sabri","year":"2015","journal-title":"Clin. Transl. Imaging"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","article-title":"Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project","volume":"75","author":"Pelkmans","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/13554794.2013.791867","article-title":"Impact of \u00b9\u2078F-florbetapir PET imaging of \u03b2-amyloid neuritic plaque density on clinical decision-making","volume":"20","author":"Zannas","year":"2014","journal-title":"Neurocase"},{"key":"ref_146","unstructured":"(2020, February 08). University of Zurich. Investigating the Clinical Consequences of Flutemetamol-PET-Scanning-ICH GCP-Clinical Trials Registry. Available online: https:\/\/ichgcp.net\/clinical-trials-registry\/NCT02353949."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work","volume":"33","author":"Delacourte","year":"2000","journal-title":"Brain Res. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40478-019-0682-x","article-title":"The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?","volume":"7","author":"Fichou","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., and Kudo, Y. (2016). Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules, 6.","DOI":"10.3390\/biom6010007"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/jnen\/64.5.420","article-title":"Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias","volume":"64","author":"Mott","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","article-title":"Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau)","volume":"45","author":"Dickson","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fnins.2018.00585","article-title":"Imaging Protein Misfolding in the Brain Using \u03b2-Sheet Ligands","volume":"12","author":"Harada","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between Abeta, tau, and alpha-synuclein: Acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","article-title":"Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline","volume":"283","author":"Haroutunian","year":"2000","journal-title":"JAMA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1523\/JNEUROSCI.1738-05.2005","article-title":"Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer\u2019s disease","volume":"25","author":"Okamura","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awr038","article-title":"18F-THK523: A novel in vivo tau imaging ligand for Alzheimer\u2019s disease","volume":"134","author":"Okamura","year":"2011","journal-title":"Brain"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","article-title":"Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease","volume":"54","author":"Okamura","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00259-013-2681-7","article-title":"In vivo evaluation of a novel tau imaging tracer for Alzheimer\u2019s disease","volume":"41","author":"Villemagne","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11307-015-0879-8","article-title":"Preclinical Evaluation of (18)FTHK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer","volume":"18","author":"Tago","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/brain\/awu064","article-title":"Non-invasive assessment of Alzheimer\u2019s disease neurofibrillary pathology using 18F-THK5105 PET","volume":"137","author":"Okamura","year":"2014","journal-title":"Brain"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13195-016-0204-z","article-title":"Regional tau deposition measured by 18FTHK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer\u2019s disease","volume":"8","author":"Almkvist","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","article-title":"Imaging in-vivo tau pathology in Alzheimer\u2019s disease with THK5317 PET in a multimodal paradigm","volume":"43","author":"Chiotis","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2967\/jnumed.115.166652","article-title":"Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease","volume":"57","author":"Tago","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2967\/jnumed.115.164848","article-title":"18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease","volume":"57","author":"Harada","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_165","first-page":"35","article-title":"Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer\u2019s disease: A combined positron emission tomography\/magnetic resonance imaging study","volume":"9","author":"Sone","year":"2017","journal-title":"Alzheimers Dement."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"996","DOI":"10.2967\/jnumed.116.182980","article-title":"In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317","volume":"58","author":"Betthauser","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2174\/0929867043364784","article-title":"Structure and mechanism of monoamine oxidase","volume":"11","author":"Edmondson","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.2174\/0929867043364810","article-title":"Monoamine oxidases: certainties and uncertainties","volume":"11","author":"Tipton","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-018-0556-7","article-title":"Neuroimaging-pathological correlations of 18FTHK5351 PET in progressive supranuclear palsy","volume":"6","author":"Ishiki","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2967\/jnumed.117.197426","article-title":"Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease","volume":"59","author":"Harada","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jsb.2004.08.002","article-title":"The binding of thioflavin-T to amyloid fibrils: localisation and implications","volume":"149","author":"Krebs","year":"2005","journal-title":"J. Struct. Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.2967\/jnumed.114.139550","article-title":"Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology","volume":"55","author":"Hashimoto","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/mds.27013","article-title":"Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to \u03b1-synuclein pathology","volume":"32","author":"Koga","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/mds.27029","article-title":"PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins","volume":"32","author":"Arena","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_176","unstructured":"Hsieh, C.-J., Mach, R.H., Zhude, T., and Kotzbauer, P.T. (2019, December 08). Imaging of Aggregated Alpha-Synuclein in Parkinson\u2019s Disease: A Work in Progress. Available online: http:\/\/s3.amazonaws.com\/rdcmssnmmi\/ files\/production\/public\/FileDownloads\/MiGateway_2_2018_final.pdf."},{"key":"ref_177","unstructured":"Cashion, D.K., Chen, G., Kasi, D., Kolb, H.C., Liu, C., Sinha, A., Szardenings, A.K., Wang, E., Yu, C., and Zhang, W. (2019, December 08). Imaging Agents for Detecting Neurological Disorders. Available online: https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2011119565."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"(18)FT807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimers Dement."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3233\/JAD-2012-120712","article-title":"A highly selective and specific PET tracer for imaging of tau pathologies","volume":"31","author":"Zhang","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand F-18-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"P842","DOI":"10.1016\/j.jalz.2013.08.003","article-title":"Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer\u2019s disease","volume":"9","author":"Mintun","year":"2013","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_182","first-page":"764","article-title":"Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies","volume":"140","author":"Ono","year":"2017","journal-title":"Brain"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mds.26857","article-title":"18 F-AV-1451 binds to putamen in multiple system atrophy","volume":"32","author":"Cho","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Kolb, H.C., and Andr\u00e9s, J.I. (2017). Tau Positron Emission Tomography Imaging. Cold Spring Harb. Perspect. Biol., 9.","DOI":"10.1101\/cshperspect.a023721"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","article-title":"Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles","volume":"57","author":"Hostetler","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.27271","article-title":"The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases","volume":"33","author":"Vermeiren","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2967\/jnumed.115.170910","article-title":"Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects","volume":"58","author":"Wooten","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2967\/jnumed.115.170027","article-title":"Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease","volume":"57","author":"Shcherbinin","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Declercq, L., Celen, S., Lecina, J., Ahamed, M., Tousseyn, T., Moechars, D., Alcazar, J., Ariza, M., Fierens, K., and Bottelbergs, A. (2016). Comparison of New Tau PET-Tracer Candidates With 18FT808 and 18FT807. Mol. Imaging, 15.","DOI":"10.1177\/1536012115624920"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11910-019-0962-7","article-title":"Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography","volume":"19","author":"Wang","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","article-title":"18FGTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer\u2019s disease","volume":"46","author":"Marik","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2967\/jnumed.116.182881","article-title":"Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects","volume":"58","author":"Barret","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_195","unstructured":"Seki, C., Tagai, K., Shimada, H., Takahata, K., Kubota, M., Takado, Y., Shinitoh, H., Kimura, Y., Ichise, M., and Okada, M. (2020, February 18). Establishment of a Simplified Method to Quantify [18F]PM-PBB3 ([18F]APN-1607) Binding in the Brains of Living Human Subjects. Available online: https:\/\/repo.qst.go.jp\/?action=pages_view_main&active_action=repository_view_main_item_detail&item_id=78239&item_no=1&page_id=13&block_id=21."},{"key":"ref_196","unstructured":"(2019, December 10). 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer\u2019s Disease, Other Dementias and Normal Controls-Full Text View-ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03625128."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnagi.2018.00174","article-title":"Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology","volume":"10","author":"Brendel","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.118.209916","article-title":"Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects","volume":"59","author":"Wong","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1021\/acs.jmedchem.7b00632","article-title":"Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer\u2019s Disease with Positron Emission Tomography","volume":"60","author":"Gobbi","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2967\/jnumed.117.196741","article-title":"Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease","volume":"59","author":"Honer","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer F-18-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Normandin","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","article-title":"Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo2,3-cpyridin-1-yl)isoquinolin-5-amine ((18)F-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)","volume":"59","author":"Walji","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","article-title":"In vivo quantification of neurofibrillary tangles with 18FMK-6240","volume":"10","author":"Pascoal","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls","volume":"60","author":"Betthauser","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_205","unstructured":"(2019, December 08). [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)-Full Text View-ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02562989."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2967\/jnumed.116.185199","article-title":"Preclinical Evaluation of 18F-JNJ64349311, a Novel PET Tracer for Tau Imaging","volume":"58","author":"Declercq","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","article-title":"Neuroimaging in Parkinson disease: from research setting to clinical practice","volume":"10","author":"Politis","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria","volume":"8","author":"Dickson","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1016\/j.bmc.2012.06.023","article-title":"Synthesis and in vitro evaluation of \u03b1-synuclein ligands","volume":"20","author":"Yu","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Bagchi, D.P., Yu, L., Perlmutter, J.S., Xu, J., Mach, R.H., Tu, Z., and Kotzbauer, P.T. (2013). Binding of the radioligand SIL23 to \u03b1-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055031"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/app4010066","article-title":"Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging \u03b1-Synuclein","volume":"4","author":"Zhang","year":"2014","journal-title":"Appl. Sci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nbd.2007.07.018","article-title":"Differentiating Alzheimer disease-associated aggregates with small molecules","volume":"28","author":"Honson","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","article-title":"Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for \u03b1-Synuclein Fibrils","volume":"58","author":"Chu","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1021\/acsomega.7b01897","article-title":"Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in Vitro","volume":"3","author":"Hsieh","year":"2018","journal-title":"ACS Omega"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbrc.2007.06.162","article-title":"Aurones serve as probes of beta-amyloid plaques in Alzheimer\u2019s disease","volume":"361","author":"Ono","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.bmc.2007.07.052","article-title":"Novel chalcones as probes for in vivo imaging of beta-amyloid plaques in Alzheimer\u2019s brains","volume":"15","author":"Ono","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1021\/jm050635e","article-title":"Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain","volume":"48","author":"Ono","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_218","first-page":"650794","article-title":"Effects of Various Flavonoids on the \u03b1-Synuclein Fibrillation Process","volume":"2010","author":"Meng","year":"2010","journal-title":"Parkinsons. Dis."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.bbagen.2012.12.027","article-title":"Oxidized quercetin inhibits \u03b1-synuclein fibrillization","volume":"1830","author":"Zhu","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1021\/bi0600749","article-title":"Small molecule inhibitors of alpha-synuclein filament assembly","volume":"45","author":"Masuda","year":"2006","journal-title":"Biochemistry"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1021\/ja4052922","article-title":"Smart near-infrared fluorescence probes with donor-acceptor structure for in vivo detection of \u03b2-amyloid deposits","volume":"136","author":"Cui","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"44305","DOI":"10.1039\/C6RA02710E","article-title":"Structure\u2013activity relationships of radioiodinated diphenyl derivatives with different conjugated double bonds as ligands for \u03b1-synuclein aggregates","volume":"6","author":"Ono","year":"2016","journal-title":"RSC Adv."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00259-018-4029-9","article-title":"Highlights of the 30th Annual Congress of the EANM, Vienna 2017: \u201cYes we can-make nuclear medicine great again\u201d","volume":"45","author":"Fanti","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_224","unstructured":"Wester, H.-J., and Yousefi, B.H. (2019, December 24). US20170157274A1-Compounds Binding to Neuropathological Aggregates-Google Patents. Available online: https:\/\/patents.google.com\/patent\/US20170157274A1\/en."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/4\/977\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:59:55Z","timestamp":1760173195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/4\/977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":224,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["molecules25040977"],"URL":"https:\/\/doi.org\/10.3390\/molecules25040977","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]}}}